Catalyst Pharmaceuticals - CPRX Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CPRX shares.
View CPRX analyst ratings or view top-rated stocks.

4 Wall Street research analysts have issued 1 year price objectives for Catalyst Pharmaceuticals' stock. Their CPRX share price forecasts range from $15.50 to $25.00. On average, they predict the company's share price to reach $21.50 in the next year. This suggests a possible upside of 34.2% from the stock's current price.
View analysts price targets for CPRX or view top-rated stocks among Wall Street analysts.

Catalyst Pharmaceuticals' stock was trading at $18.60 at the beginning of 2023. Since then, CPRX shares have decreased by 13.9% and is now trading at $16.02.
View the best growth stocks for 2023 here.

Catalyst Pharmaceuticals saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 10,370,000 shares, an increase of 6.5% from the February 13th total of 9,740,000 shares. Based on an average trading volume of 2,360,000 shares, the short-interest ratio is currently 4.4 days. Approximately 10.6% of the shares of the stock are sold short.
View Catalyst Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023.
View our CPRX earnings forecast.

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) posted its quarterly earnings data on Tuesday, November, 9th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.10. The biopharmaceutical company had revenue of $35.95 million for the quarter, compared to analysts' expectations of $34.47 million. Catalyst Pharmaceuticals had a trailing twelve-month return on equity of 32.21% and a net margin of 38.78%. During the same quarter last year, the firm earned $0.11 earnings per share.

ETFs with the largest weight of Catalyst Pharmaceuticals (NASDAQ:CPRX) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), Aztlan Global Stock Selection DM SMID ETF (AZTD), Invesco Dynamic Biotechnology & Genome ETF (PBE), Invesco DWA Healthcare Momentum ETF (PTH), Invesco S&P SmallCap Health Care ETF (PSCH), Invesco S&P SmallCap 600 Pure Growth ETF (RZG), AdvisorShares Alpha DNA Equity Sentiment ETF (SENT) and Invesco S&P SmallCap Momentum ETF (XSMO).

Catalyst Pharmaceuticals issued an update on its fourth quarter 2022 earnings guidance on Tuesday, February, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $61.00 million-$61.00 million, compared to the consensus revenue estimate of $56.84 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NVAX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), Verastem (VSTM), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL) and TherapeuticsMD (TXMD).

Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPRX."

Catalyst Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Millennium Management LLC (2.22%), Dimensional Fund Advisors LP (2.22%), Two Sigma Investments LP (1.85%), Two Sigma Advisers LP (1.74%), Geode Capital Management LLC (1.69%) and Morgan Stanley (1.67%). Insiders that own company stock include Alicia Grande, Brian Elsbernd, Charles B O'keeffe, David S Tierney, Donald A Denkhaus, Gary Ingenito, Patrick J Mcenany, Philip H Coelho, Preethi Sundaram and Steve Miller.
View institutional ownership trends.

Shares of CPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CPRX stock can currently be purchased for approximately $16.02.

Catalyst Pharmaceuticals (NASDAQ:CPRX) has a market capitalization of $1.69 billion and generates $214.20 million in revenue each year. The biopharmaceutical company earns $83.08 million in net income (profit) each year or $0.74 on an earnings per share basis.

Catalyst Pharmaceuticals' mailing address is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. The official website for the company is www.catalystpharma.com. The biopharmaceutical company can be reached via phone at (305) 420-3200, via email at bkorb@troutgroup.com, or via fax at 305-529-0933.